Onco360® Selected By Rigel Pharmaceuticals As Limited Distribution Specialty Pharmacy For TAVALISSE®, GAVRETO®, And REZLIDHIA®

Onco360®, the nation’s leading independent specialty pharmacy, has been selected by Rigel Pharmaceuticals as a limited distribution specialty pharmacy partner for TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib), and REZLIDHIA® (olutasidenib).

Benito Fernandez, Chief Commercial Officer of Onco360, said the company is excited to serve as one of Rigel Pharmaceuticals’ national specialty pharmacy providers and to expand its portfolio of limited distribution therapies. He emphasized that Onco360’s mission is to provide the highest level of personalized service, clinical expertise, and compassionate support to patients and their caregivers.

With a dedicated focus on oncology, rare, and complex diseases, Onco360 combines national reach with clinical innovation. The company is committed to improving patient access and adherence, backed by a consistent emphasis on quality and service.